Trevena Inc.

Trevena has carved out a niche in seeking so-called 'biased ligands'--GPCR-binding compounds that selectively activate just one (or a few) of the many biological pathways mediated via a particular GPCR complex. By identifying a ligand that hits the pathways responsible for a medicine's benefits, and avoiding those behind the ill effects, the company hopes to develop safer and more effective therapies, initially in CNS and cardiovascular disease.